Office of Research
Clinical Trials

Evaluating brain injury from subdural hematomas using advanced imaging

We hope to conduct advanced MRIs on patients. We think these MRIs will help better understand how subdural hematomas injure the brain and keep people from fully recovering once the blood goes away.

Imaging Voice After Laryngectomy

Adults who have had their voice box removed and use a voice prosthesis may join during a regular clinic visit. A special camera is added briefly to the routine exam to record how tissues vibrate to create voice. The study does not change care and offers no direct benefit.

Brain Imaging in Hearing Loss

Adults with and without hearing loss will undergo MRI scans to study brain changes related to hearing.

Brain and spine imaging before and after neck surgery for instability

This research study is looking at how advanced MRI scans can show changes in the brainstem and upper spine in people with craniocervical instability or a condition called basilar invagination. Participants will have MRI scans before surgery and again after surgery as part of their regular care, with one additional special scan. Researchers will compare these images to see how the spine and brainstem change after treatment and whether these changes relate to symptoms and recovery. The goal is to improve how doctors measure treatment success and better understand which patients may benefit from surgery.

CAPTIVA MRI Biomarker Study

This is an observational MRI study done alongside the CAPTIVA clinical trial. People already enrolled in CAPTIVA who had a recent non-disabling stroke from severe narrowing (70-99%) of an intracranial artery can join. Participants get a detailed MRI scan within 14 days of CAPTIVA enrollment to look at artery plaque and blood flow. The study will follow participants for about 12 months to see if MRI features can help predict who will have another ischemic stroke in the same artery despite medical therapy. The goal is to find imaging markers that could guide future trials and improve care for patients with intracranial artery narrowing.

Cannabidiol for Focal Seizures Study

This is an open-label, single-group study testing a cannabidiol (CBD) oral solution as an extra medicine for people with focal-onset seizures aged 12 to 75. Participants will keep their current anti-seizure medicines (1 to 4 drugs) and add the CBD solution. The main goal is to see whether CBD lowers the number of focal seizures compared to each person's baseline over about 16 weeks. The study will also look at safety, how the body handles the drug (pharmacokinetics), and whether brain imaging (fMRI) or thinking tests predict who responds best. Some people in the study may be early in their treatment and others may have hard-to-treat seizures. The study does not include people with non-epileptic events, recent CBD or cannabis use, certain allergies, or unstable medical or mental-health issues.

Comparing Surgical Options for Treating Recurrent Carpal Tunnel Symptoms After a Prior Release

This study compares three different surgical approaches used when carpal tunnel symptoms return after a previous surgery. Some people experience relief at first, but symptoms later come back, and doctors must decide which type of revision surgery will give the best results. Because there is not enough research comparing these options, this study is designed to help provide clearer answers. Adults who have recurrent carpal tunnel symptoms and have tried nonsurgical treatments such as splinting or injections may qualify to participate. After completing a baseline evaluation, including hand strength testing and questionnaires, participants are randomly assigned to one of three revision procedures. All three techniques are currently used in clinical practice. After surgery, participants will return for follow‑up visits at several points over two years. At each visit they will complete surveys and have simple hand function checks to track improvement in symptoms, comfort, and daily use of the hand. By comparing recovery, hand function, and symptom improvement across different revision procedures, the study aims to help surgeons choose the best option for future patients. The study also looks at whether pre‑surgery symptoms, nerve test results, or imaging findings can help predict how well someone will recover after revision surgery.

Acupuncture for Sickle Cell Pain

This research tests whether acupuncture can reduce pain in people with sickle cell disease and how it affects the brain and blood markers. Participants 14–80 years old who have chronic sickle cell pain are randomly assigned to receive ten sessions (30 minutes each) of either traditional needle acupuncture or non-needle laser acupuncture. The main treatment period includes about 14 in-person visits over roughly 6–8 weeks. Investigators will collect pain and health questionnaires, perform sensory testing before and after treatments, and record brain activity using MRI, fNIRS, and EEG. During imaging, controlled pain stimuli will be applied to the lower leg. Blood samples will be taken before and after the treatment course to study biomarkers, and a noninvasive inner-eyelid image will be used to estimate hemoglobin. Participants will be followed monthly for up to 12 months after the in-person visits to track pain and quality of life. Some procedural details are not provided now to preserve study integrity.

Studying Shoulder Replacement Outcomes Using a Custom Baseplate for Severe Glenoid Bone Loss

This study looks at how well people do after a reverse shoulder replacement when they have severe bone loss in the socket of the shoulder (the glenoid). In these cases, a standard implant may not fit securely, so surgeons use a custom‑designed baseplate created from each patient's CT scan. The goal is to better understand early recovery, function, and implant stability in patients who receive these individualized implants. Patients who had this surgery between 2021 and 2024 and are willing to participate will be included. The study collects information from past medical records and from a new clinic visit. During this visit, patients complete short questionnaires about shoulder function and pain and undergo a routine exam that measures how far the shoulder can move. Patients also receive a CT scan so researchers can check how stable the baseplate is and whether screws or components have shifted. All surgeries were already completed as part of normal medical care. The study does not involve any new procedures, additional surgery, or experimental treatments. The custom baseplates used were designed from CT imaging to match each patient's anatomy and were implanted by a shoulder specialist. The information gathered will help surgeons understand how well these custom implants perform in the first months after surgery and whether they offer advantages for people with major glenoid bone loss. Findings may guide future treatment decisions and improve the quality of care for shoulder replacement patients with complex anatomy.

Adjuvant Radiation for Pleural Mesothelioma

This randomized Phase 3 study compared two approaches for treating stage I-IIIA malignant pleural mesothelioma that is suitable for pleurectomy/decortication (P/D). All patients received surgery to remove visible tumor and standard chemotherapy (pemetrexed with cisplatin or carboplatin). Half of the patients were randomly assigned to also get adjuvant hemithoracic intensity-modulated pleural radiation therapy (IMPRINT), a targeted form of radiation to the chest lining, while the other half received no additional radiation. The main goal was to see if adding IMPRINT improves overall survival. Secondary goals included measuring local control, spread to distant sites, progression-free survival, treatment-related side effects, and quality of life. The study also planned exploratory analyses of staging accuracy, surgical outcomes, biomarkers, and radiation dose effects. After treatment, patients were followed frequently for the first 2 years and then every 6 months for up to 5 years. The trial was terminated early, so only limited outcome data were available.

This study may be appropriate for those with: Newly Diagnosed Cancer

Neladalkib vs Alectinib in ALK NSCLC

This is a global Phase 3 study that will randomly assign people with ALK-positive advanced non-small cell lung cancer (who have not had prior systemic treatment for their lung cancer) to one of two first-line treatments: neladalkib (NVL-655) or alectinib. About 450 participants will be split evenly between the two drugs. The main goal is to see which drug keeps the cancer from getting worse for a longer time, using independent radiology review. Other goals include overall survival, brain (intracranial) outcomes, tumor response rates, safety and side effects, and patient-reported quality of life. Treatment continues until the cancer progresses or side effects prevent further treatment. Participants will be followed with regular scans and visits, and some measures will be collected for up to five years after the first patient is dosed.

This study may be appropriate for those with: Metastatic Cancer

Comparing Two Surgical Approaches for Fixing Posterior Malleolus Fragments in Ankle Fractures

This study looks at two accepted surgical approaches used to repair a specific part of the ankle-the posterior malleolus-in patients who have trimalleolar ankle fractures. In some patients, surgeons directly fix the broken piece of bone in the back of the ankle. In others, surgeons use indirect techniques to reduce and stabilize the fragment without directly exposing it. Both methods are commonly used today, but it is not known which leads to better stability and long‑term recovery. Patients who require surgery and meet the study's criteria will be invited to participate. Before surgery, each person receives standard X‑rays and a CT scan, and fills out questionnaires about their daily function and overall health. During surgery, after the main ankle bones are fixed, the surgeon performs a series of stress tests on the ankle joint to see whether the syndesmosis-the ligaments between the tibia and fibula-needs to be stabilized. These tests are standard and help determine the best treatment for each patient. The surgery itself and all choices about implants, positioning, and fixation are made by the treating surgeon based on their usual clinical practice. After surgery, patients return for checkups at about 6 weeks, 3 months, 6 months, and 12 months. At these visits, patients complete short surveys about pain, activity, and function, and receive routine X‑rays (except at the initial 2‑week wound check). The goal of the study is to find out whether directly fixing the posterior malleolus fragment leads to better ankle stability, fewer complications, and improved function compared with indirect treatment. The study does not add extra costs, procedures, or risks beyond standard care. What we learn may help guide future treatment decisions and improve recovery for patients with this type of ankle fracture.

Endovascular Treatment in Disabled Stroke

This is a prospective, observational study at multiple stroke centers to compare two commonly used care approaches for people who had moderate-to-severe disability before getting a large-vessel ischemic stroke. One approach is standard medical care (medications, blood pressure and cholesterol control, rehab and other supportive measures) and the other adds endovascular thrombectomy (mechanical removal of the clot). The study will enroll adults with pre-stroke disability (moderate to severe) who arrive within 24 hours of stroke symptoms and have a large artery blockage on brain imaging. The main goal is to compare how patients do at about 90 days after treatment-measuring functional outcome, return to prior level, quality of life, and safety (including death and bleeding in the brain). Results aim to guide care decisions for stroke patients who already had disabilities before their stroke.

Measuring Swallowing in Healthy Adults

Healthy adults will undergo ultrasound imaging while swallowing to establish normal movement patterns.

Study on BAY 2927088 for Lung Cancer with HER2 Mutations

This study is examining a new treatment called BAY 2927088 for people with advanced non-small cell lung cancer (NSCLC) that involves specific changes in the HER2 gene. The goal is to see how well this drug works compared to standard chemotherapy. Participants will receive either the new medication orally or standard chemotherapy via infusions. Doctors will use imaging tests like CT and MRI scans to track cancer progress, along with various health tests. The study aims to observe progression-free survival and overall survival rates, and assess safety through the observation of side effects and adverse reactions.

This study may be appropriate for those with: Metastatic Cancer

Amivantamab Versus Cetuximab in cSCC

This study is testing a new treatment approach for people with cutaneous squamous cell skin cancer that has come back or spread and who have weakened immune systems. Participants are placed into one of two groups. One group gets amivantamab given under the skin together with hyaluronidase to help the drug stay in the body longer. The other group gets cetuximab given into a vein. Treatment is given in 28-day cycles for up to about 24 cycles unless the cancer gets worse or side effects are too severe. Doctors will check safety, how well the cancer responds, and how long people live without cancer growth. Blood tests and scans will be done throughout treatment, and some patients will be followed afterward for years. The study also collects samples for future research.

This study may be appropriate for those with: Metastatic Cancer

Bladder Preservation Immunoradiation

This Phase II study tests whether combining the immune drug pembrolizumab with radiation therapy can allow people with muscle invasive bladder cancer to keep their bladder after the tumor has already shrunk from pre-surgery chemotherapy. Eligible patients have an excellent clinical response after neoadjuvant chemotherapy and will receive daily photon radiation to the bladder Monday through Friday for up to about 4 weeks while also getting pembrolizumab through an IV every 3 weeks. Before joining, patients have had a TURBT (a bladder tumor biopsy/removal procedure) and staging scans. The study tracks how long patients keep their bladder without cancer returning, whether they later need bladder removal (salvage cystectomy), survival outcomes, side effects, and patient-reported symptoms. Blood, urine, and tissue samples will be stored for future research. After finishing treatment, participants are followed regularly for up to 5 years.

This study may be appropriate for those with: Newly Diagnosed Cancer

STRATEGY FOR IMPROVING STROKE TRMT RESP

SISTER is a Phase-2, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alpha-2 antiplasmin (a2-AP), in acute ischemic stroke.

Exercises to Improve Swallowing After Stroke

Adults who have swallowing problems after stroke will perform tongue exercises or a comparison activity. Swallowing tests before and after help determine if exercises improve function.

Studying Swallowing With Ultrasound

Adults with normal or swallowing problems will have ultrasound imaging during swallowing tasks to better understand how the tongue and throat move. This may improve future swallowing evaluations.

Letrozole Study in Recurrent High Grade Gliomas

Patients will receive up to 20 mg of letrozole orally each day both before and after surgical resection. The primary endpoint of this study is the measurement of tumoral bioavailability of letrozole.

This study may be appropriate for those with: Recurrent Cancer

ExoFlo EVs for ARDS Phase III

This Phase III randomized, double-blind, placebo-controlled trial tests an intravenous extracellular vesicle product called ExoFlo (from bone marrow mesenchymal stem cells) in hospitalized adults with moderate-to-severe ARDS. Participants receive either a single IV dose of ExoFlo (15 mL) or a matched placebo and are followed in hospital with assessments and additional follow-up through about Day 61. The main goal is to see if ExoFlo lowers 60-day all-cause mortality compared with placebo. Secondary goals include time to death, ventilator-free days, oxygen-free days, ICU-free days, and the rate of serious adverse events. Key eligibility includes adults 18-75 with ARDS that started within 7 days and meets clinical and imaging criteria; main exclusions include recent major trauma, long prior ventilation (>72 hours), severe liver disease, pregnancy, DNR status, ECMO, or recent investigational treatments.

Testing Venetoclax for Relapsed Hairy Cell Leukemia

This study is investigating the effectiveness of the drug venetoclax in patients whose hairy cell leukemia has returned after initial treatment. Venetoclax works by blocking a protein necessary for cancer cell survival, potentially reducing cancer growth. Participants will take venetoclax daily in cycles, and their response will be monitored through medical tests, including blood samples and imaging scans. The study aims to measure the overall response rate, complete remission, and any side effects. Eligible participants are those who have not had prior venetoclax treatment and meet specific health criteria. People with certain conditions or allergies should not participate. The study will follow participants for 30 days after their last medication dose to assess outcomes.

This study may be appropriate for those with: Relapsed / Refractory Cancer

Pasritamig With Docetaxel Study

This phase 3 trial tests whether adding pasritamig to standard chemotherapy (docetaxel) helps men with metastatic castration resistant prostate cancer live longer without their disease getting worse on scans. Eligible men must have prostate adenocarcinoma that has spread, be on hormone lowering treatment or surgically castrated, have had at least one prior androgen receptor targeted therapy, and be in generally good health for cancer treatment. Participants are randomly assigned to receive pasritamig plus docetaxel or docetaxel alone. Doctors will use imaging scans to track when the cancer progresses, and will also measure overall survival, pain and quality of life, PSA blood changes, need for more treatment, bone related problems, tumor response if measurable, and side effects. Blood tests, scans, and questionnaires are used during treatment and for follow up. The main question is whether the combination delays radiographic progression compared with chemotherapy alone.

This study may be appropriate for those with: Metastatic Cancer

Stroke Cognitive Recovery Study

This is a large, observational study that will enroll about 8,000 people who are hospitalized with a recent stroke and who do not have known dementia. The study looks at how thinking and memory change after stroke and what factors influence recovery. All participants complete a baseline check, blood sample, and short thinking and daily function tests. They have follow up visits in person at about 3 to 6 months and 18 months, and yearly phone check ups up to four years. Some participants join extra tiers that include brain MRI scans and more detailed thinking tests and blood draws. A smaller group gets special PET scans that look for proteins linked to dementia. The study follows people over time to learn which stroke features, imaging findings, blood markers, and other risks lead to more or less cognitive decline.

Blood Test for Traumatic Brain Injury

This study will enroll adults who come to the emergency department after a head injury and have a head CT scan as part of their care. The research has two parts: one aims to develop a blood test that helps diagnose TBI and predict recovery, and the other follows hospitalized patients to see if blood markers can detect new or worsening brain problems while in hospital. Participants will have blood samples taken early after injury and be followed with clinical checks, imaging done for care (CT or MRI), and outcome assessments at about 2, 14, 28, and 90 days. The study will compare blood marker results with imaging, clinical judgment, and standard outcome scales to find whether the blood test can accurately identify injury, predict recovery, and spot secondary events.

Comparing Two Surgical Options for Stabilizing Metastatic Bone Disease in the Upper Thigh (PERFORM)

The PERFORM study is a major international research trial comparing two ways of treating cancer‑related bone disease in the upper part of the thigh bone (proximal femur). Some patients develop weak or broken bones in this area when cancer spreads to the skeleton, and surgery is often needed to help them walk safely and reduce pain. The study compares two surgical options: Resection and reconstruction - removing the damaged section of bone and replacing it with an implant. Internal fixation - strengthening the bone using plates, screws, or a rod placed inside the bone. Patients who qualify will be randomly assigned to one of the two procedures. Doctors want to know which option helps patients live longer, stay mobile, and spend more days at home during the year after surgery. The study also measures quality of life, physical function, pain levels, and time spent in hospitals or care facilities. About 334 patients from hospitals across Canada, the U.S., and other countries will participate. Everyone will be followed for one year after their surgery, with check‑ins and questionnaires at several time points. All surgeries and follow‑up visits are standard medical care. The goal of PERFORM is to provide strong evidence to guide surgeons on the best treatment for people with metastatic bone disease in the femur. By comparing these two common surgical approaches, the study will help determine which one offers better long‑term outcomes and quality of life for cancer patients.

Understanding Flare-Ups in Chronic Sinusitis

This study aims to understand why people with chronic sinus problems sometimes experience sudden flare-ups. Adults with chronic sinusitis will have nasal samples taken during a flare-up and again about a month later. The study does not change medical care but may help improve future treatments.

PPMI

The Parkinson Progression Marker Initiative 2.0 (PPMI 2.0) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls. The overall goal of PPMI 2.0 is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.

Vaccine Trial for Adults with Severe RRP

This study is testing a vaccine for adults with repeated airway growths that often need surgery. Participants receive four vaccine injections and are followed to see if surgery is needed less often and if symptoms improve.

AMXT1501 and DFMO With Standard Care

This open-label Phase 1b/2 study tests two oral drugs, AMXT 1501 and DFMO, given together with standard treatments in people with advanced ER+ / HER2- breast cancer or with unresectable or metastatic cutaneous melanoma. AMXT 1501 blocks tumor uptake of polyamines and DFMO lowers polyamine production; together they aim to reduce tumor-supporting molecules and possibly improve responses to standard therapy. In the breast cancer group the combo is given with fulvestrant and capivasertib. In the melanoma group the combo is given with pembrolizumab. The Phase 1b part uses a small dose-escalation plan to find a safe dose for Phase 2. The Phase 2 part will look for signs the treatment controls or shrinks tumors using standard tumor response rules. The study also checks drug levels in blood, changes in tumor tissue and immune genes, and overall safety. About 92 patients may be enrolled across the two groups. Participants will have screening tests, regular clinic visits each treatment cycle (28 days), imaging to measure response, and follow-up visits.

This study may be appropriate for those with: Metastatic Cancer

APT Acute TBI Adaptive Multi-Arm Phase 2 Platform Trial

This is a randomized, parallel, multi-arm, multi-stage adaptive Phase 2 platform trial testing whether repurposed FDA-approved drugs given off-label soon after injury can improve recovery after acute non-penetrating traumatic brain injury (TBI). Adults 18-65 who present within 24 hours of injury with a Glasgow Coma Scale (GCS) 9-15, CT evidence of intracranial trauma (CT+), and an elevated GFAP blood level (>100 pg/mL) are eligible. Participants are randomized to one of the investigational drug arms or placebo. Investigational agents vary by arm and are selected for potential neuroprotective and anti-inflammatory effects to reduce secondary injury. Participants undergo serial clinical assessments, blood biomarker sampling (including GFAP and NfL), cognitive testing, and MRI (including DTI). The primary efficacy outcome compares change in the Glasgow Outcome Scale-Extended (GOSE) between Week 2 and Month 3. Secondary outcomes include biomarker trajectories, DTI measures, cognitive performance, and post-concussive symptom scales. Follow-up visits occur through Month 6 with approximately six in-person visits plus interim phone assessments and scheduled imaging/blood draws. Safety monitoring excludes participants with significant comorbidities, pregnancy, known contraindications to study drugs, or abnormal renal/hepatic function, among other criteria. The trial uses an adaptive platform design allowing multiple investigational arms to be evaluated sequentially or concurrently against placebo.

Cemiplimab CDX-1140 Before Surgery

This is a randomized phase 2 study for adults with stage III or IV head and neck squamous cell cancer who are scheduled for surgery. Patients are placed into one of two groups. One group receives cemiplimab (an anti PD‑1 immunotherapy) before surgery. The other group receives one dose of the anti‑CD40 drug CDX‑1140 followed a few days later by cemiplimab before surgery. Surgery is planned about 4 to 5 weeks after treatment. After surgery patients receive standard care as needed and are followed for up to two years. The main goal is to compare how often the removed tumor shows a major pathologic response (very little viable cancer left) between the two groups. The study also checks safety and side effects, looks at tumor and blood markers (including gene expression and circulating tumor DNA), studies immune changes in the tumor, and measures drug levels. Visits include screening tests, treatment infusions, the surgery visit, and follow up visits at about weeks 9–10 and 18, at 6 months, and then every 3–6 months for two years.

This study may be appropriate for those with: Metastatic Cancer

Combining Iadademstat with Immunotherapy for Advanced Lung Cancer

This clinical research study is investigating if adding iadademstat to traditional immunotherapy drugs, atezolizumab or durvalumab, can improve outcomes for people with small cell lung cancer that has spread extensively. The study aims to determine the safest dose of iadademstat, examine any side effects, and see how well it works in combination with the other drugs. In phase I, the study is testing different doses of iadademstat with either atezolizumab or durvalumab to find the safest and most effective amount. Phase II will test the chosen dose against the use of immunotherapy alone in maintaining cancer control after the initial treatment. Participants will continue treatment in cycles and will be monitored through various exams including scans and blood tests. The goal is to see if this combination can stabilize the cancer longer compared to using only traditional immunotherapy. This large and carefully monitored trial allows participants who meet specific health criteria, like confirmed extensive-stage small cell lung cancer diagnosis, a stable condition on immunotherapy, and ability to take oral medication. While the study is an opportunity for advanced treatment options, it comes with specific inclusion and exclusion criteria based on health conditions and earlier treatments to ensure safety.

This study may be appropriate for those with: Newly Diagnosed Cancer

Pasritamig for Advanced Prostate Cancer

This is a late‑stage phase 3 study testing pasritamig (JNJ‑78278343), a medicine that redirects a person's T cells to target a prostate cancer protein, in people with metastatic castration‑resistant prostate cancer (mCRPC) whose disease has progressed after standard treatments. Participants are randomly assigned to receive pasritamig plus best supportive care or placebo plus best supportive care. The main goal is to compare overall survival between the two groups. Other goals include measuring time to disease progression by imaging, time to symptom or pain worsening, time to events in the bones, lab changes, and side effects. Participants must be on ongoing hormone suppression and have already received available life‑prolonging therapies appropriate for them. The study follows participants for up to about 2 years and 8 months to assess outcomes.

This study may be appropriate for those with: Metastatic Cancer

One Stop Cervical Screening System

This study will test a new, low‑cost system that uses urine spectroscopy and artificial intelligence (AI) on cervical photos to screen and triage women for cervical cancer in Zimbabwe. The project has two parts. In Part 1 (about 2 years) researchers will collect urine and self‑collected vaginal samples from about 1,100 women to improve the urine spectroscopy AI and compare its results to a standard HPV test. They will also collect more cervical images to improve the image‑reading AI and teach it to recognize the transformation zone type. In Part 2 (about 3 years) around 2,100 women will be screened with the AI urine test and a validated HPV test. Women who test positive will have colposcopy, cervical imaging, and biopsy if needed. The study will measure how well the AI urine test and the AI image triage detect histology‑confirmed CIN2+ (high grade precancer or cancer) compared with standard tests, and will check how well AI determines the transformation zone type. The team will also compare costs versus current local practice. Most participants will have one screening visit. HPV‑positive women will return for colposcopy, biopsy, and treatment if required. The study is carried out by IARC with partners in Zimbabwe and other institutions.

Videofluoroscopic Swallowing Norms

This study will use videofluoroscopy (a moving X-ray of swallowing) to measure how people of different ages swallow. The team will test about 280 healthy adults across the adult age span and will also collect data from three clinical groups at risk for swallowing problems: people with Parkinson disease, people with COPD, and people recently having had a stroke. The goal is to build clear normal ranges for swallowing measures (like airway protection, residue left after swallowing, timing of airway closure, and how well the throat squeezes) and to find practical cutoff points that help tell normal from disordered swallowing. The results aim to help clinicians interpret swallowing tests more reliably and guide diagnosis and treatment decisions.

TAPUR Study: FDA Approved Drugs Targeting Tumor Gene Abnormalities

The TAPUR Study is focused on understanding how FDA-approved drugs that target specific abnormalities in tumor genes work for patients with advanced cancers. These include solid tumors, multiple myeloma, and non-Hodgkin lymphoma that have a detectable genetic feature that can potentially be treated with these medicines. The study evaluates participants' responses, safety of treatments, survival rates, and helps to form ideas for new clinical trials based on real-world usage of these therapies. Anyone aged 12 or older with certain advanced cancers whose condition can be measured and who meets other criteria may participate. However, those with certain conditions like primary brain tumors or unmeasurable disease may not be eligible.

This study may be appropriate for those with: Relapsed / Refractory Cancer

Post Stroke Sensory Reweighting

This is a small observational study that follows people who had an ischemic stroke to understand how their brain and body adjust the way they use sensory information for balance and walking (called sensory reweighting). Participants are approached in the hospital and enrolled within 14 days of the stroke, and return for testing at about 2, 4, and 6 months after the stroke. At each visit the team measures leg strength and function, balance, walking speed, and records any falls. Participants also have brain imaging at the 6 month visit to look for structural patterns linked to changes in balance and walking. The goal is to find early, measurable signs and brain features that explain why some people recover better than others and to help design more precise rehabilitation and brain stimulation targets.

Study on Alzheimer's Disease Risk in Adults with Down Syndrome

This study aims to form a trial-ready group of adults with Down Syndrome (DS). It includes 120 healthy participants aged 25-55. Researchers will conduct cognitive and clinical tests to analyze relationships between brain markers and cognitive abilities. The goal is to improve future Alzheimer's clinical trials, focusing on disease patterns specific to people with DS. Participants will share data with another ongoing study for more comprehensive research outcomes.

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients with high-risk well-differentiated pancreatic neuroendocrine tumors.

This study may be appropriate for those with: Newly Diagnosed Cancer

CLL/SLL- Received 2nd G BTKi+/-Obinutuzu

In this phase II, multicenter trial, we seek to test the hypothesis that administration of up to 12 cycles of epcoritamab following a 12 months or greater time period of acalabrutinib +/- obinutuzumab or zanubrutinib +/- obinutuzumab in patients who have attained a partial response or better will have a high CR conversion rate with uMRD that enables discontinuation of therapy and lead to durable remission. Additionally, Patients attaining this exceptional uMRD CR at completion of therapy will have evidence of autologous T-cell response toward the patient pre- treatment CLL cells. A safety lead in of the combination for the first 9 patients followed by Simon's 2 stage design will be implemented. Following our inclusion and exclusion criteria, eligible patients will be treated with subcutaneous epcoritamab for a total of 12 cycles while continuing their BTKi therapy. Patients will be assessed for disease response as defined by the iw-CLL 2018 response criteria following completion of cycle 6 and 12 of epcoritamab by peripheral blood labs, CT imaging and bone marrow biopsy for morphology and flow cytometry (if labs/imaging indicating CR) and MRD status through NGS assay (ClonoSEQ). MRD will be performed from bone marrow samples if BMBx is done, and if not done peripheral blood sample will be used for MRD status. Patients with undetectable MRD will stop treatment after completing the consolidative epcoritamab treatment. If patients or their treating physician desire them to stay on BTKi, they may elect to do so. Those who have dMRD will be monitored for disease progression with consideration of starting back on BTKi monotherapy if they showed any signs of PD. All patients who complete 12 cycles of epcoritamab consolidative therapy will have the ability to continue BTKi as monotherapy regardless of MRD status, pending discussion with the patient and treating-physician.

This study may be appropriate for those with: Newly Diagnosed Cancer

Comparing Surgical vs Nonsurgical Care for Fragility Pelvic Fractures: The FLIPER Pilot Study

Fragility fractures of the pelvis are increasing as the population ages. Doctors often treat these injuries either with surgery or with nonsurgical care focused on early movement and rehabilitation. It is not yet clear which option works best for which patients, and previous studies have had limitations. The FLIPER pilot study is designed to prepare for a larger, more definitive study by testing whether it's practical to compare these treatments fairly and safely. People aged 60 and older with a specific type of low‑energy pelvic fracture (LC1) may be eligible. After consent, the research team collects information from the hospital chart and from the patient or a family member. The care team decides whether surgery or nonsurgical care is best, based on their usual clinical judgment. About four months after the injury, participants (or their caregivers) are contacted to see how they are doing. The study focuses on three important outcomes at about four months: Survival (whether the patient is still living), Ability to walk across a room, and "Days at home," meaning the number of days not spent in a hospital or facility. The team will also ask patients and surgeons if they would be willing to take part in a future randomized study that directly compares surgery to nonsurgical care. This helps researchers learn whether a larger trial would be acceptable and realistic. No experimental treatments are involved. All care decisions are made by the medical team as part of normal practice. The information learned from this pilot will guide the design of a larger study to improve treatment decisions and outcomes for older adults with fragility pelvic fractures.

Study of Ipatasertib with Chemoradiation for Head and Neck Cancer

This study is testing if a new drug, ipatasertib, can improve treatment when added to the usual chemotherapy and radiation for advanced head and neck cancer. Ipatasertib could help stop cancer growth by targeting specific proteins in cancer cells. The study aims to find the best dosage alongside existing treatments. It's primarily for patients with advanced stages of head and neck squamous cell carcinoma. Participants must be 18 or older, able to swallow pills, and meet certain health criteria. The study examines safety, necessary dosage, and treatment effectiveness. Patients will receive ipatasertib and typical cancer treatments over a set schedule and undergo various imaging tests. After treatment, they'll be monitored periodically up to two years. This research hopes to improve survival rates and better control cancer growth through this novel treatment combination.

This study may be appropriate for those with: Newly Diagnosed Cancer

Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

This study aims to determine whether rectal cancer's response to treatment is the same when patients receive chemotherapy alone before limited surgery versus when they receive both chemotherapy and radiation therapy before limited surgery, and if omitting radiation therapy improves quality of life.

This study may be appropriate for those with: Newly Diagnosed Cancer

Higher Dose Radiation Therapy for Advanced Pancreatic Cancer Trial

This study is exploring if giving higher doses of radiation can help people with advanced pancreatic cancer live longer. Participants must have already undergone 4-6 months of chemotherapy and have stable disease without progression. There are two groups in the study. One group will receive standard treatment, which could include continuing chemotherapy, a normal dose of radiation, or observation. The other group will receive higher doses of radiation over a shorter period to see if it prolongs their survival. Patients will have regular follow-ups and will be checked through blood tests, imaging scans, and tissue biopsies. They are monitored over a period that includes every three-month checkups for two years and then yearly for another three years. This study aims to not only see if survival improves but examine side effects, quality of life, and any changes in disease progression.

This study may be appropriate for those with: Metastatic Cancer

Testing Abemaciclib with 5-Fluorouracil for Metastatic Colorectal Cancer

This clinical trial is investigating how well two drugs, Abemaciclib and 5-Fluorouracil (5-FU), work together in treating people with colorectal cancer that has spread to other parts of the body and hasn't responded to other treatments. The study aims to discover the safest dose of the drug combination that patients can handle without severe side effects. Participants will take Abemaciclib by mouth twice daily, and receive 5-FU through a vein on specific days during each 28-day cycle. Throughout the study, various samples will be collected to track the effectiveness and side effects of the treatment. After finishing the treatment cycles, participants will be monitored every three months for follow-up. Researchers hope this combination will provide a new option for those with this difficult-to-treat cancer type.

This study may be appropriate for those with: Metastatic Cancer

DeciPHer ILD Patient Registry

This is a multi-center, non-interventional registry that will follow people who have pulmonary hypertension caused by interstitial lung disease. About 1,000 patients will join one of three groups: not using inhaled treprostinil, newly started on Tyvaso or Tyvaso DPI, or on Tyvaso/Tyvaso DPI for more than 60 days. Participants will have tests and questionnaires done at enrollment and then every 6 or 12 months, using results already recorded when available. The study will collect lung tests and scans, walking test results, blood tests, heart imaging, quality of life surveys, medication and rehab details, healthcare use, transplant and survival information, and other clinical data. Patients will be followed for up to five years to learn more about patient characteristics, treatment patterns, and outcomes in real-world care.

Efficacy and Safety of Trimodulin in Severe Pneumonia Patients

This study is exploring the effectiveness and safety of a drug called trimodulin in treating adults with severe community-acquired pneumonia who are on ventilators. Participants will receive either trimodulin or a placebo, along with standard medical care. The main goal is to see if trimodulin can reduce death rates and improve recovery. The trial will monitor subjects closely over 29 days, with an additional follow-up until day 91 to check long-term effects, safety, and overall health improvements. The study also involves collecting detailed data on how trimodulin is processed in the body, aiming to improve current treatments for this serious illness.

Alzheimer's National Registry for Treatment and Diagnostics

The ALZ-NET study is establishing a national registry to collect ongoing clinical and safety information for patients being evaluated for or treated with new FDA-approved therapies for Alzheimer's disease. This effort will help track how well these treatments work over time and their safety outcomes in everyday medical settings. Participating doctors and staff will receive training to ensure accurate data collection. By gathering a wide range of information, including cognitive and safety data as well as genetic and imaging biomarkers, ALZ-NET aims to improve care and support innovative research. They also plan to store biological samples and brain images from consenting participants. The study is open to adults 18 and older who are either considering, starting, or currently on new Alzheimer's treatments.

Blood Test for ctDNA in Guiding Immunotherapy After Bladder Cancer Surgery

This study investigates whether a blood test can detect leftover cancer after bladder surgery and guide further treatment using immunotherapy. It aims to identify patients who might need additional treatment to prevent cancer from coming back. The study uses blood tests to look for circulating tumor DNA (ctDNA), which can indicate cancer presence. Patients testing positive for ctDNA might receive immunotherapy drugs nivolumab and relatlimab, while those who test negative might not get additional treatment immediately. This research hopes to improve survival rates and quality of life for bladder cancer patients by tailoring immunotherapy based on ctDNA results.

This study may be appropriate for those with: Newly Diagnosed Cancer

Study of Ficerafusp Alfa and Pembrolizumab for Head and Neck Cancer

This study focuses on patients with certain types of head and neck cancers that have come back or spread. Researchers are testing a drug called ficerafusp alfa along with pembrolizumab, comparing it to a placebo with pembrolizumab. The aim is to see if the combination is safe and works better than the placebo. The study will happen in two phases. The first phase selects the best dose of ficerafusp alfa. The second phase will see how effective the treatment is when compared to a placebo, with patients randomly assigned to receive either the active treatment or a placebo. Key goals include measuring the response rate of tumors and overall survival among participants, while watching for side effects.

This study may be appropriate for those with: Newly Diagnosed Cancer

Precision Ventilation for ARDS

This is a Phase 3 randomized trial testing whether a personalized way of setting the ventilator can save more lives for patients with moderate to severe ARDS. Patients are randomly assigned to one of two approaches while on a breathing machine. The experimental arm uses an esophageal catheter to measure pressures inside the chest and guides ventilator settings to keep lung stress in a normal range. The control arm receives guided usual care with standard low tidal volume ventilation; esophageal pressure readings are recorded but not shown to the care team. The main measure is death from any cause within 60 days. The study will also look at 28‑day death, time alive and free from the ventilator, need for advanced respiratory support, lung injury markers in blood, breathing complications such as pneumothorax, blood pressure stability, organ function scores, and ICU and hospital length of stay. The goal is to see if precision ventilation reduces lung injury and improves recovery without causing extra harm.

LTI03 Phase 2 IPF Study

This study tests LTI-03, an experimental inhaled medicine, in people with idiopathic pulmonary fibrosis (IPF). The drug is given as powder capsules that participants inhale using a device. About 120 people with IPF diagnosed within the past 5 years will be randomly assigned to low or high dose LTI-03 or matching placebo and neither they nor the study staff will know which they receive. The study includes a 28-day screening period, 24 weeks of treatment, and a 4-week follow-up. Participants will make up to nine clinic visits for safety checks, breathing tests, blood samples, symptom questionnaires, and lung scans at the start and end of treatment. The study will look at side effects and whether LTI-03 affects lung scarring, lung function, and symptoms compared with placebo.

DLBCL GCB Treatment Study

This is a phase 2 randomized study for people with newly diagnosed germinal center B-cell (GCB) subtype diffuse large B-cell lymphoma (DLBCL). It compares two treatment combinations given with standard chemo (R-CHP): zilovertamab vedotin (MK-2140) plus R-CHP versus polatuzumab vedotin plus R-CHP. The main goal is to see which group has more people with a complete response to treatment at the end of therapy, as measured by imaging reviewed independently. The study also follows participants for progression-free survival, overall survival, event-free survival, how long responses last, side effects, and quality of life measures. People must have PET-positive disease, no prior DLBCL treatment, and certain infections must be controlled to join. Some people are not eligible due to other lymphoma types, serious heart issues, active infections, significant nerve problems, recent other cancers, or recent transplants.

This study may be appropriate for those with: Recurrent Cancer

Relacorilant With Chemo for Pancreas

This is a Phase 2, single-arm study testing relacorilant combined with standard chemotherapy (nab-paclitaxel and gemcitabine) in people with newly diagnosed metastatic pancreatic ductal adenocarcinoma. Participants take relacorilant by mouth around the days they receive chemotherapy. Chemotherapy infusions are given on Days 1, 8, and 15 of each 28-day cycle. Treatment continues until the cancer gets worse, side effects cannot be managed, or another stopping reason occurs. The study will measure how long patients live without cancer growth, overall survival, tumor responses, changes in a tumor blood marker (CA19-9), safety, and drug levels in the blood.

This study may be appropriate for those with: Metastatic Cancer

Testing Ado-Trastuzumab Emtansine Compared to the Usual Treatment for Salivary Gland Cancer

A CONTROLLED, RANDOMIZED PHASE II TRIAL OF DOCETAXEL PLUS TRASTUZUMAB VERSUS ADO-TRASTUZUMAB EMTANSINE FOR RECURRENT, METASTATIC, OR TREATMENT-NAÏVE, UNRESECTABLE HER2-POSITIVE SALIVARY GLAND CANCER

This study may be appropriate for those with: Metastatic Cancer

Radiation With Cetuximab or Chemotherapy

This phase 3 trial compares two treatments given with high-precision radiation therapy (IMRT) for people with advanced head and neck cancer who cannot take cisplatin. Patients are randomly placed into one of two groups. One group gets weekly cetuximab (a drug that targets the EGFR protein on some cancer cells) together with 35 daily radiation treatments over about 7 weeks. The other group gets weekly carboplatin and paclitaxel chemotherapy together with the same radiation schedule. Patients have scans and blood tests during the study and are followed after treatment at 30 days, then at 4, 6, 12, 18, 24, 30, and 36 months and then yearly. The main goal is to compare progression-free survival between the two groups. Secondary goals include comparing overall survival, side effects, where the cancer returns if it does, and changes in eating and speaking function.

This study may be appropriate for those with: Metastatic Cancer

Rebalance Study May Health

This is a multicenter randomized study testing the May Health System, a device used to treat ovarian tissue through the vagina while guided by ultrasound. The goal is to restore ovulation for women with PCOS-related infertility who did not get results from standard first-line ovulation medicines or who cannot or will not use those medicines. Participants are randomly assigned to have the procedure or to a control group; people in the control group may choose the procedure after the main 3‑month visit. The main measure is whether a woman has at least one ovulation within 3 months. Safety and side effects will be tracked through 36 months. Other measures include ovulation rates to 6 months, time to first ovulation, pregnancies, hormone levels, pain after the procedure, daily activity ability, and procedure times. Eligible women are 18-40, actively trying to conceive, and meet clinical and imaging criteria for PCOS with at least one reachable ovary. The study excludes those who are pregnant, have certain medical conditions (for example serious bleeding disorders, uncontrolled diabetes, very high androgen levels), prior ovarian surgery, or other factors that raise risk or would affect results.

Using Ultrasound to Track Median Nerve Recovery After Carpal Tunnel Release Surgery

Carpal tunnel release is a common surgery for relieving pressure on the median nerve in the wrist. While most patients improve, some continue to have symptoms. This study explores whether ultrasound can help track the healing of the median nerve after surgery and whether changes seen on ultrasound relate to how patients feel and function. Ultrasound is quick, painless, and widely available. Before surgery, patients will have an ultrasound exam that measures the size of the median nerve and blood flow within it. These same measurements will be repeated at later follow‑up visits. Researchers will look at whether the nerve becomes smaller, less swollen, or changes in blood flow as healing occurs. Patients also complete simple questionnaires about hand function, symptoms, and daily activities. Doctors will check strength, sensation, and other routine exam findings. By comparing ultrasound images with patient‑reported outcomes, the study aims to learn whether ultrasound could become an easy way to measure recovery after carpal tunnel surgery. All surgeries, exams, and imaging are part of standard care except for the additional research‑guided ultrasound assessments. The information gained may help future patients and doctors better understand the healing process and identify early signs of improvement or persistent problems.

Comparing Two Stemless Shoulder Replacement Implants to Improve Function and Patient Outcomes

This study compares two different stemless shoulder replacement implants-the Nano and Sidus components-to learn whether one offers better function, comfort, or recovery for patients needing an anatomic total shoulder arthroplasty (TSA). Both implants are FDA‑approved and routinely used by the surgeon, and the surgery itself follows standard medical practice. Adult patients who are recommended for TSA by Dr. Grawe may be invited to participate. After giving consent, they complete a few short questionnaires about shoulder function and general health, and their range of motion is measured. They are then randomly assigned to receive either the Nano or the Sidus implant. Randomization ensures a fair comparison between the two options. The shoulder replacement surgery is performed in the usual way, with the only difference being the specific stemless implant used. After surgery, patients return for checkups at approximately 6 months, 12 months, and 24 months. At each visit, they complete the same questionnaires and have X‑rays and range of motion testing to evaluate healing and progress. The goal of this research is to determine whether one implant provides better outcomes than the other and to help surgeons choose the best option for future patients. There are no additional procedures, costs, or risks beyond standard care, and both implants represent established shoulder replacement options already widely used in clinical practice.

Sac TMT Maintenance in Ovarian Cancer

This late-stage (Phase 3) study is testing a new maintenance option for people with newly diagnosed advanced ovarian cancer whose tumors are HRD-negative. Participants will have already had surgery and first-line platinum-based chemotherapy and shown no disease growth or some response. The study compares sacituzumab tirumotecan (an antibody-drug therapy) given as maintenance, with or without the targeted drug bevacizumab, to the usual standard care (which may include observation or bevacizumab maintenance). The main goal is to find out if the study treatment keeps cancer from getting worse for longer. Researchers will also track overall survival, later disease progression after new treatments, safety and side effects, and quality of life measures using standard questionnaires. Participants will have regular clinic visits for treatment, scans, and assessments during the treatment and for long-term follow-up. The full study follow-up can last several years to measure how long benefits and side effects last.

This study may be appropriate for those with: Newly Diagnosed Cancer

Panitumumab for KRAS Wild Type Pancreas

This is a phase III randomized trial for adults with pancreatic ductal adenocarcinoma that cannot be removed by surgery or that has spread, whose tumors are KRAS wild type and BRAF V600E wild type by tissue testing. Participants are assigned to one of two groups. One group receives standard second line chemotherapy (one of several standard regimens) alone. The other group receives the same chemotherapy plus panitumumab, an antibody that targets EGFR on tumor cells. Treatment is given in 28 day cycles, typically with drug infusions on days 1 and 15, and continues until the cancer progresses or side effects are unacceptable. The main goal is to see whether adding panitumumab improves overall survival. The study also compares tumor response, progression free survival, side effects, and quality of life. Blood and tumor samples may be collected and stored for future research. Participants are followed for up to three years after randomization.

This study may be appropriate for those with: Metastatic Cancer

ShortStop HER2 Duration Study

This phase 3 study tests whether people with early HER2-positive breast cancer who have no invasive cancer left after pre-surgery chemotherapy (a pathologic complete response) can safely get a shorter course of HER2-targeted therapy. Participants are randomly assigned to receive trastuzumab (with or without pertuzumab, based on their doctor's choice) for either about 6 months or about 12 months given every three weeks by IV or as a subcutaneous shot. The trial looks mainly at whether cancer recurrence-free survival with 6 months is no worse than with 12 months. It also compares patient-reported quality of life and side effects, and tracks serious side effects, overall survival, and time to brain recurrence. Patients have heart checks and routine imaging during treatment. After treatment, people are followed every 6 months for 5 years, then yearly up to 10 years total.

This study may be appropriate for those with: Newly Diagnosed Cancer

IMGN151 in Gynecologic Cancers

This Phase 1b study tests IMGN151, an investigational cancer drug, in adults with gynecologic cancers. About 377 people will join at about 50 sites. Participants are placed into treatment groups: IMGN151 given with carboplatin, with olaparib, with bevacizumab, or as IMGN151 alone. The main goals are to find dose‑limiting toxicities and to assess safety and side effects over the study period, and to look for early signs that tumors respond (shrink or stop growing). Participants must have good performance status, most need at least one measurable tumor by scan, and must meet timing rules for prior treatments. People with certain ovarian tumor types, prior FRα‑targeting therapy, large prior radiation to the marrow, or other significant medical issues are not allowed. The study lasts about 3 years overall. Participants will come for regular clinic visits for infusions, blood tests, and scans and will stay on treatment until disease progression, unacceptable side effects, or other reasons to stop.

This study may be appropriate for those with: Newly Diagnosed Cancer

Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma

The purpose of this research is to study if a decrease in the dose of radiation to regions which have no visible cancer will be as effective as the standard dose. The dose to all visible cancer remains unchanged to the standard radiation approach. The researchers believe that a lower dose could be just as helpful for treating your cancer, while reducing the side effects of radiation and improving quality of life. The current standard care treatment for OPSCC can have debilitating side effects. The researchers believe that using a decreased dose of 30 Gy from 46-54 Gy to regions without visible cancer but which have a risk of microscopic cancer might be just as effective for treating your cancer with less side effects. The combination of these approaches is not considered the current standard of care and will be considered research. You will continue to receive standard systemic therapy of cisplatin during your radiation therapy.

This study may be appropriate for those with: Newly Diagnosed Cancer

Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery

This phase II trial evaluates the effectiveness of administering durvalumab alongside the standard chemotherapy regimen of gemcitabine and cisplatin prior to surgery in patients with high-risk, surgically removable liver cancer (cholangiocarcinoma). Durvalumab, a monoclonal antibody, may block tumor growth and spread. Gemcitabine and cisplatin, chemotherapy drugs, work to halt tumor cell proliferation by various mechanisms. The combination of durvalumab with these chemotherapies before surgery aims to shrink the tumor and minimize the removal of healthy tissue in patients with high-risk resectable cholangiocarcinoma.

This study may be appropriate for those with: Newly Diagnosed Cancer

Phase 2 Study of ACR-368 in Endometrial Cancer

This Phase 2 study tests ACR-368 in people with high-grade endometrial cancer. Participants are placed into one of three groups. Arms 1 and 2 use a lab test called OncoSignature to predict sensitivity to ACR-368: Arm 1 (OncoSignature Positive) receives ACR-368 alone; Arm 2 (OncoSignature Negative) receives ACR-368 plus ultra-low dose gemcitabine (ULDG). Arm 3 (no OncoSignature testing) also receives ACR-368 with ULDG; EU sites enroll only to Arm 3. Treatment continues until the cancer gets worse, side effects become unacceptable, or the person stops. The main goal is to measure tumor response by CT or MRI every 8 weeks for up to 2 years. Safety, some drug levels in blood, overall survival, time without cancer growth, and duration of any response are also tracked. Key eligibility includes prior platinum chemotherapy and prior anti-PD-(L)1 therapy, measurable disease, and adequate overall health. Certain conditions like uncontrolled viral infections, serious heart disease, recent major surgery or recent cancer treatment, symptomatic brain metastases on high-dose steroids, bowel obstruction, or prior CHK1 inhibitor use will exclude people from joining.

This study may be appropriate for those with: Relapsed / Refractory Cancer

PPF Block for Post SAH Headache

This is a phase II, randomized, double‑blind trial testing whether a bilateral pterygopalatine fossa (PPF) injection can reduce opioid use for acute headache after an aneurysmal subarachnoid hemorrhage (SAH). Participants who are adults hospitalized soon after a spontaneous SAH and who need strong opioid pain medicine are randomized to receive either an active PPF block (ropivacaine plus dexamethasone) or a saline injection as a placebo. The study compares opioid use in the 24 hours after each injection across a 48‑hour double‑blind period. Safety is monitored with imaging to check for radiographic vasospasm at 48 hours, and tolerability is measured by whether participants accept a second injection at 24 hours. The trial also measures intracranial artery flow with transcranial Doppler around the time of the injections to watch for changes. The goal is to find a safer, opioid‑sparing way to treat severe headache after SAH without increasing the risk of vasospasm.

CARTISTEM Debridement Knee Trial

This is a randomized, double-blind Phase 3 trial testing CARTISTEM against standard surgical debridement in adults with a moderate knee cartilage defect and knee osteoarthritis. CARTISTEM is a treatment made from donated umbilical cord blood stem cells mixed into a gel that is placed into the cartilage defect during surgery. Participants will be randomly assigned to receive CARTISTEM or debridement and will be followed for 24 months. The main goals are to see whether CARTISTEM reduces pain (measured by a 0–100 pain scale) and improves knee function (WOMAC function score) more than debridement at two years. The study will also use MRI scans to look at cartilage repair and osteoarthritis changes. People must meet health and imaging requirements and agree to the study rules and rehabilitation program to take part.

A Multicenter Phase 2 Study of LP-168 and Obinutuzumab for Previously Treated and T474 Gatekeeper Mutant CLL/SLL

This is a phase II research study being conducted at multiple locations. It is designed to test the combination of obinutuzumab and LP‑168 in two groups of people with CLL/SLL: those who have been treated before, and those whose disease has a specific genetic change that makes it harder to treat with standard therapies.Participants will take LP‑168 once a day, starting on the first day of treatment, for up to 12 treatment cycles. About two weeks after finishing the first six cycles, their progress will be checked using blood tests, imaging scans, and a bone marrow sample. After this check‑in, participants will continue taking LP‑168 and will also begin receiving obinutuzumab. Obinutuzumab will be given over six cycles, starting in cycle 7, on several scheduled days early on and then once per cycle through cycle 12. Everyone will receive at least 12 cycles of treatment. At the end of cycle 12, participants will be evaluated again to see how well the treatment worked. This will include blood tests, scans if needed, and examination of blood and bone marrow samples to look for any remaining signs of disease. Participants whose disease is no longer detectable at that point may choose to stop treatment. Those who still have signs of disease will continue taking LP‑168 and will be followed every six months. Additional testing may be done later, and treatment can be stopped if no disease is detected at that time.

This study may be appropriate for those with: Recurrent Cancer

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)

COLON ADJUVANT CHEMOTHERAPY BASED ON EVALUATION OF RESIDUAL DISEASE (CIRCULATE-US)

This study may be appropriate for those with: Newly Diagnosed Cancer